Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 8/20 | 0.43 |
| ▸ | PPARD | Q03181 | 8/20 | 0.43 |
| ▸ | PPARA | Q07869 | 8/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | FABP4 | P15090 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1783778 | 0.78 | CES2 (0.41) | AKR1B1PPARGPPARDPPARAGPR84 | |
| SCHEMBL9313819 | 0.78 | TSHR (0.40) | AKR1B1PPARGPPARDPPARAGPR84 | |
| SCHEMBL1783776 | 0.78 | CES2 (0.41) | AKR1B1PPARGPPARDPPARAGPR84 | |
| SCHEMBL8926956 | 0.77 | TSHR (0.39) | AKR1B1PPARGPPARDPPARAGPR84 | |
| SCHEMBL1784001 | 0.77 | TSHR (0.43) | PPARGPPARDPPARAGPR84HDAC11 | |
| SCHEMBL1784002 | 0.77 | TSHR (0.43) | PPARGPPARDPPARAGPR84HDAC11 | |
| SCHEMBL3361824 | 0.77 | AKR1B1 (0.46) | AKR1B1PPARGPPARDPPARAGPR84 | |
| SCHEMBL3361822 | 0.77 | AKR1B1 (0.46) | AKR1B1PPARGPPARDPPARAGPR84 | |
| SCHEMBL25425408 | 0.75 | GPR84 (0.48) | AKR1B1PPARGPPARDPPARAGPR84 | |
| SCHEMBL9997344 | 0.75 | GPR84 (0.48) | AKR1B1PPARGPPARDPPARAGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030010-B2 | Method for detecting a biomarker of oxidative stress in a biological sample | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2011-10-04 | — | — | US | claimed |
| US-20090111121-A1 | METHOD FOR DETECTING A BIOMARKER OF OXIDATIVE STRESS IN A BIOLOGICAL SAMPLE | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2009-04-30 | — | — | US | claimed |
| EP-1934602-A4 | METHOD FOR DETECTING A BIOMARKER OF OXIDATIVE STRESS IN A BIOLOGICAL SAMPLE | INST CARDIOLOGIE MONTREAL (CA) | 2009-01-21 | — | — | EP | claimed |
| EP-1934602-A1 | METHOD FOR DETECTING A BIOMARKER OF OXIDATIVE STRESS IN A BIOLOGICAL SAMPLE | Institut de Cardiologie de Montréal (CA) | 2008-06-25 | — | — | EP | claimed |
| WO-2007041868-A1 | METHOD FOR DETECTING A BIOMARKER OF OXIDATIVE STRESS IN A BIOLOGICAL SAMPLE | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2007-04-19 | — | — | WO | claimed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-20230047393-A1 | COMPOSITION CONTAINING AN ALK5 INHIBITOR, EW-7197 | EWHA DrugDesignHouse Co.,Ltd. (KR) | 2023-02-16 | — | — | US | disclosed |
| WO-2023013993-A1 | COMPOSITION OR METHOD CONTAINING AN ALK5 INHIBITOR, EW-7197 | EWHA DRUGDESIGNHOUSE CO., LTD. (KR) | 2023-02-09 | — | — | WO | disclosed |
| EP-4069868-A2 | METHODS OF DETECTION AND ANALYSIS OF NUCLEIC ACID IN NEURAL-DERIVED EXOSOMES | The Institute For Ethnomedicine DBA Brain Chemistry Labs (US) | 2022-10-12 | — | — | EP | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| WO-2009132050-A2 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009096905-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-08-06 | — | — | WO | disclosed |
| US-20090170789-A1 | Antioxidants for preventing and treating diseases caused by oxidative stress | GITLIN ISAAK GRIGORIEVICH | 2009-07-02 | — | — | US | disclosed |
| EP-2065045-A1 | ANTIOXIDANT FOR PREVENTING AND TREATING DISEASES CAUSED BY OXIDATIVE STRESS | Gitlin, Isaak Grigorievich (RU) | 2009-06-03 | — | — | EP | disclosed |
| US-20090111121-A1 | METHOD FOR DETECTING A BIOMARKER OF OXIDATIVE STRESS IN A BIOLOGICAL SAMPLE | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2009-04-30 | — | — | US | disclosed |
| EP-1934602-A4 | METHOD FOR DETECTING A BIOMARKER OF OXIDATIVE STRESS IN A BIOLOGICAL SAMPLE | INST CARDIOLOGIE MONTREAL (CA) | 2009-01-21 | — | — | EP | disclosed |
| EP-1934602-A1 | METHOD FOR DETECTING A BIOMARKER OF OXIDATIVE STRESS IN A BIOLOGICAL SAMPLE | Institut de Cardiologie de Montréal (CA) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007041868-A1 | METHOD FOR DETECTING A BIOMARKER OF OXIDATIVE STRESS IN A BIOLOGICAL SAMPLE | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | AKR1B1 1457/4885PPARG 263/4885PPARD 232/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | AKR1B1 1641/4885PPARG 2125/4885PPARD 2300/4885 |
| US-20230047393-A1 | COMPOSITION CONTAINING AN ALK5 INHIBITOR, EW-7197 | ALK, TGFBR1, TGFBR2 | AKR1B1 2528/4885PPARG 867/4885PPARD 1027/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | AKR1B1 1641/4885PPARG 2125/4885PPARD 2300/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | AKR1B1 1641/4885PPARG 2125/4885PPARD 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.